Company Overview and News

0
Stock With Momentum: Kumpulan Perangsang Selangor

2018-06-26 theedgemarkets
SHARES in Kumpulan Perangsang Selangor Bhd (KPS) (fundamental: 1.15/3, valuation: 2/3) triggered our proprietary momentum algorithm yesterday for the ninth time this year.
7171 5843

4
Kumpulan Perangsang chairman quits

2018-06-05 thestar.com.my
PETALING JAYA: Kumpulan Perangsang Selangor Bhd (KPS), the company controlled by the Selangor state government, saw its chairman Raja Datuk Idris Raja Kamarudin resigning from his post.
7171 5843 BSMAF 1818

4
Kumpulan Perangsang Q1 revenue up 25%

2018-06-04 thestar.com.my
KUALA LUMPUR: Kumpulan Perangsang Selangor Bhd ’s net profit for the first quarter ended March 31declined to RM13.21mil from RM20.21mil in the same period last year.
7171 5843 BSMAF 1818

0
Trading ideas: Ikhmas Jaya, Symphony Life, UCrest, KPS, Gamuda

2018-04-10 thestar.com.my
KUALA LUMPUR: JF Apex Research expects Ikhmas Jaya Group Bhd, Symphony Life Bhd , UCrest Bhd, Kumpulan Perangsang Selangor Bhd (KPS) and Gamuda Bhd to generate trading interest following their latest corporate news.
7171 5843 1538 5268

0
CBB enters into JV with China-based Honda Printing to produce boxes

2018-04-09 thestar.com.my
KUALA LUMPUR: Century Bond Bhd (CBB), a subsidiary of Kumpulan Perangsang Selangor Bhd (KPS), has entered into a joint-venture (JV) agreement with China-based Honda Printing Holdings Ltd (Honda Printing) to produce offset carton boxes for the manufacturing sector.
7171 5843

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...